Vistagen Therapeutics, Inc. (VTGN) bonds
VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/3078% below fair value
$0.19+0.00 (+2.01%)
Close on Nov 17, 2026Market cap $8.34MP/E –Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Vistagen Therapeutics reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
When the debt comes due
Principal repayments of long-term debt by fiscal year, as scheduled at Mar 31, 2016
From the debt maturity table in the annual report (filing). “Later” is everything due after year five.
Notes and loans outstanding
As tagged in Vistagen Therapeutics's 10-Q for the period ended May 31, 2025
| Issue | Coupon | Amount issued |
|---|---|---|
| Promissory Note | 6.54% | $1.00M |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.
See a number that looks wrong?